Syndax claims biomarker predicts increased benefit of HDAC/PD-1 combination in NSCLC

Genetic research laboratory at Keesler AFB (Image: Kemberly Groue / U.S. Air Force)
Syndax has decided not to pursue further studies of its entinostat-Keytruda combination in melanoma at this time, without the potential biomarker data like it found in NSCLC. (Kemberly Groue/U.S. Air Force)

Syndax Pharmaceuticals’ combination of its HDAC inhibitor entinostat with Merck’s anti-PD-1 therapy Keytruda may have posted small gains in an ongoing phase 1b/2 study in non-small cell lung cancer, but the company believes it has identified an enrichment biomarker that could predict increased clinical benefit overall.

In 57 patients that had progressed after chemotherapy and PD-1 treatments, six showed partial responses to the entinostat-Keytruda combination, for an 11% objective response rate. The median duration of response was 4.6 months, according to Syndax.

Blood samples identified a subset of patients with higher baseline levels of classical blood monocytes that appeared to fare better with the combination regimen: with an ORR of 29% and a progression-free survival of 5.4 months, the subset nearly doubled the 2.8-month benefit seen in historical NSCLC patients treated with third-line chemotherapy.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

By comparison, patients with lower monocyte levels had an ORR of 5% and a PFS of 2.5 months, below the overall patient population’s 2.7.

“Monocyte levels may reflect the ability of the immune system to respond after elimination of immune suppression,” said Dmitry Gabrilovich, Christopher M. Davis Professor and leader of the immunology, microenvironment and metastasis program at The Wistar Institute. The company plans to present the study’s results at the annual meeting of the American Society of Clinical Oncology this June.

RELATED: Genentech, Syndax expand HDAC-PD-L1 combination pact

On a conference call with investors, Syndax estimated about 30,000 patients would qualify annually under this biomarker, after progressing through first-, second- or third-line treatments including PD-1 and PD-L1 inhibitors.

The company plans to launch a registration trial by the end of this year, gathering data for possible submissions in both the biomarker-enriched and the wider, “all-comers” populations in NSCLC. Syndax will meet with FDA and European officials for guidance in protocol design, with results expected in 2020.

RELATED: AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

The phase 1b/2 study also enrolled cohorts in melanoma and microsatellite stable colorectal cancer—and while objective responses were observed across all cohorts, the company’s future development plans in these areas remain uncertain.

In melanoma, an ORR of 18% has led Syndax to not consider a registration trial at this time, and instead continue biomarker analysis. The company said it would feel more comfortable with correlative data like it found in NSCLC.

In MSS-CRC, following discussions with Merck, Syndax plans to expand enrollment from 16 to 37 patients into the first stage of a two-stage study by the end of the second quarter. Three responses will be required to advance to the second stage, where an additional 47 patients would be enrolled, with that decision scheduled for the first half of next year.

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.